Show simple item record

dc.contributor.authorJiménez Carretero, Mónica
dc.contributor.authorGómez, Ana Belén
dc.contributor.authorLázaro Callejón, Marina 
dc.contributor.authorMillán-Placer, Ana Cristina
dc.contributor.authorCalogero Gaglio, Salvatore
dc.contributor.authorAnoz Carbonell, Ernesto
dc.contributor.authorPicó, Ana
dc.contributor.authorBaranyai, Zsuzsa
dc.contributor.authorJabalera Ruz, Ylenia María 
dc.contributor.authorMaqueda Abreu, Mercedes 
dc.contributor.authorCarrasco Jiménez, María Paz 
dc.contributor.authorPerduca, Massimiliano
dc.contributor.authorDe la Fuente, Jesús M.
dc.contributor.authorIglesias Salto, Guillermo Ramón 
dc.contributor.authorMontalbán López, Manuel 
dc.contributor.authorJiménez López, Concepción 
dc.contributor.authorAínsa, José A.
dc.date.accessioned2025-07-04T07:36:22Z
dc.date.available2025-07-04T07:36:22Z
dc.date.issued2025-06-20
dc.identifier.citationM. Jimenez-Carretero et al. International Journal of Biological Macromolecules 319 (2025) 145441. https://doi.org/10.1016/j.ijbiomac.2025.145441es_ES
dc.identifier.urihttps://hdl.handle.net/10481/105060
dc.descriptionThis work was supported by FEDER Operational Program [B-BIO-432-UGR20, B-CTS-216-UGR20, A-FQM-492-UGR20], Plan Andaluz de Investigación, Desarrollo e Innovación [P20–00346, P20–00233], Instituto de Salud Carlos III [PI20–01658] and Ministerio de Economía [EC2019–005930-P, PDC2021–121135.100]. The grants TED2021-131855BI00/AEI/10.13039/501100011033/Unión Europea Next Generation EU/PRTR and PID2023-151881OB-I00 (AEI, Spain).es_ES
dc.description.abstractMycobacterium tuberculosis, the etiological agent of human tuberculosis, is an intracellular pathogen responsible for one of the infectious diseases with highest mortality rates. Its ability to replicate inside alveolar macrophages and trigger the formation of granulomas, alongside the appearance of multidrug-resistant strains, impose the employment of drugs that exacerbate their toxic effects after the long therapies necessary to deal with the infection. As an alternative to conventional drugs, this work proposes the use of bacteriocin AS-48 immobilized on biomimetic magnetic nanoparticles (BMNPs) as a nanoformulation capable of killing M. tuberculosis in infected THP-1 macrophages, which allows combination with magnetic hyperthermia to increase its effectiveness. This work is a proof of concept of a nanosystem that could potentially be magnetically directed to infected areas, where it could be applied locally. Our results show that AS-48_BMNP nanoassemblies used against M. tuberculosis in vitro display a synergistic effect with magnetic hyperthermia that can completely eradicate the bacteria from infected macrophages in four days. This combined treatment represents a promising opportunity for the future development of a local therapy for the treatment of M. tuberculosis.es_ES
dc.description.sponsorshipFEDER Operational Programes_ES
dc.description.sponsorshipPlan Andaluz de Investigación, Desarrollo e Innovaciónes_ES
dc.description.sponsorshipInstituto de Salud Carlos IIIes_ES
dc.description.sponsorshipMinisterio de Economíaes_ES
dc.description.sponsorshipTED2021-131855BI00/AEI/10.13039/501100011033/Unión Europea Next Generation EU/PRTR and PID2023-151881OB-I00es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBacteriocines_ES
dc.subjectTuberculosis es_ES
dc.subjectMagnetic nanoparticleses_ES
dc.titleMagnetic hyperthermia drastically enhances killing of Mycobacterium tuberculosis by bacteriocin AS-48 grafted on biomimetic nanoparticleses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1016/j.ijbiomac.2025.145441
dc.type.hasVersionVoRes_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional